Saniona.com

Saniona.com has Server used 104.154.31.24 IP Address with Hostname in United States. Below listing website ranking, Similar Webs, Backlinks. This domain was first 2014-02-14 (7 years, 88 days) and hosted in Mountain View United States, server ping response time 44 ms

DNS & Emails Contact

This tool is used to extract the DNS and Emails from this domain uses to contact the customer.

Fetching Emails ...

Extract All Emails from Domain

Top Keywords Suggestions

Keywords suggestion tool used Saniona keyword to suggest some keywords related from this domain. If you want more, you can press button Load more »

1 Saniona
2 Saniona.com
3 Saniona ab
4 Saniona a/s
5 Saniona pws
6 Saniona logo
7 Saniona avanza
8 Saniona nasdaq
9 Saniona pharma

Hosting Provider

Website: Saniona.com
Hostname: 24.31.154.104.bc.googleusercontent.com
Country:
Region: CA
City: Mountain View
Postal Code: 94043
Latitude: 37.419200897217
Longitude: -122.05740356445
Area Code: 650
Email AbuseNo Emails Found

Find Other Domains on Any IP/ Domain


New! Domain Extensions Updated .com .org .de .net .uk   » more ...

Domains Actived Recently

   » Runen.net (2 seconds ago)

   » Inaturist.com (25 seconds ago)

   » Alfalaboratory.com (7 seconds ago)

   » H5constructionllc.com (1 seconds ago)

   » Madrasafree.net (4 seconds ago)

   » Thewayprepared.com (26 seconds ago)

   » Tecneco.com (3 seconds ago)

   » Cityofdrippingsprings.com (14 seconds ago)

   » Getbackyourgo.com (15 seconds ago)

Results For Websites Listing

Found 45 Websites with content related to this domain, It is result after search with search engine

Saniona Successfully Raises USD 65 Million (approximately

Globenewswire.com   DA: 21 PA: 50 MOZ Rank: 71

  • Saniona is a rare disease biopharmaceutical company focused on research, development and commercialization of treatments for the central nervous system
  • The company has four programs in clinical

Saniona Received Approximately USD $2.9 Million (SEK 24.2

Finance.yahoo.com   DA: 17 PA: 50 MOZ Rank: 68

Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced it received approximately USD $2.9 million (SEK 24.2 million) in …

Stock SANIONA Stock Price Today Markets Insider

Markets.businessinsider.com   DA: 27 PA: 24 MOZ Rank: 53

Saniona AB engages in the research and development on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases, and treatment of pain.

Saniona To Host Research And Development (R&D) Day On

Tmcnet.com   DA: 14 PA: 50 MOZ Rank: 67

  • 11 hours ago · Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world
  • The company’s lead product candidate, Tesomet, is in mid-stage clinical trials for hypothalamic obesity and Prader-Willi syndrome, severe rare disorders characterized by uncontrollable

Saniona Launches New Video Series To Highlight The Impact

Tmcnet.com   DA: 14 PA: 31 MOZ Rank: 49

2 days ago · Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world.

Saniona Launches New Video Series To Highlight The Impact

Biospace.com   DA: 16 PA: 50 MOZ Rank: 71

Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced its “Saniona’s Community Voices” video series, which will feature the voices of people living with rare diseases, their caregivers and their medical professionals.The serieswill launch during the month ofMay, which is both Prader-Willi syndrome (PWS) and Brain Tumor Awareness …

Saniona Video Series Highlights Impact Of PWS And

Praderwillinews.com   DA: 19 PA: 50 MOZ Rank: 75

  • A new video series from Saniona is highlighting the impact, on patients and caregivers, of Prader-Willi syndrome (PWS) and an associated condition called hypothalamic obesity
  • Called “Saniona’s Community Voices,” the series features people living …

Saniona Launches New Video Series To Highlight The Impact

Apnews.com   DA: 10 PA: 50 MOZ Rank: 67

  • 2 days ago · About Saniona Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world
  • The company’s lead product candidate, Tesomet, is in mid-stage clinical trials for hypothalamic obesity and Prader-Willi syndrome, severe rare disorders characterized by

Saniona Completes Sale Of Remaining Shares In Scandion

Globenewswire.com   DA: 21 PA: 50 MOZ Rank: 79

Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world.

Metoprolol/tesofensine

Adisinsight.springer.com   DA: 24 PA: 16 MOZ Rank: 49

  • 22 Jun 2020 Saniona plans to initiate pivotal trial for obesity over next 12 months ; 09 Jun 2020 Saniona plans a phase IIb trial for Prader-Willi syndrome in USA in second half of 2020 ; 09 Jun 2020 Metoprolol/tesofensine - Saniona is available for licensing in World as of 09 Jun 2020

Saniona AB: Saniona Announces Partnership With The

Finanznachrichten.de   DA: 24 PA: 50 MOZ Rank: 84

  • About Saniona Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world

Saniona Received Approximately USD $2.9 Million (SEK 24.2

Marketwatch.com   DA: 19 PA: 50 MOZ Rank: 80

  • About Saniona Saniona is a biopharmaceutical company focused on discovering, developing and delivering innovative treatments for rare disease patients around the world

Saniona Launches New Video Series To Highlight The Impact

Finanzen.ch   DA: 15 PA: 50 MOZ Rank: 77

  • 2 days ago · About Saniona Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world

FDA Provides Feedback To Saniona On Development Of Tesomet

Praderwillinews.com   DA: 19 PA: 50 MOZ Rank: 82

  • Saniona completed a Phase 2a trial (NCT03149445) investigating the safety and efficacy of Tesomet in young adults with PWS
  • The study found that patients receiving once-daily Tesomet showed a decrease in weight, body mass index (BMI), and hyperphagia, or excessive eating, compared with patients on a placebo.

SANION Stock Price Saniona AB Stock Quote (Sweden

Marketwatch.com   DA: 19 PA: 23 MOZ Rank: 56

  • Saniona AB engages in the research and development on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases, and treatment of pain.

Saniona Updates Tesomet Clinical Development Timelines

Sports.yahoo.com   DA: 16 PA: 50 MOZ Rank: 81

Saniona is advancing Tesomet for hypothalamic obesity and Prader-Willi syndrome, two severe rare disorders characterized by obesity and loss of …

SANION:Stockholm Stock Quote

Bloomberg.com   DA: 17 PA: 16 MOZ Rank: 49

  • Saniona AB researches and develops drugs to treat diseases of the central nervous system, autoimmune diseases, and for pain relief
  • The Company collaborates with global pharmaceutical companies to

Saniona Updates Tesomet Clinical Development Timelines

Benzinga.com   DA: 16 PA: 50 MOZ Rank: 83

Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it received feedback from …

Notice Of Saniona AB Annual Shareholders' Meeting

Marketscreener.com   DA: 22 PA: 50 MOZ Rank: 90

Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world.

Saniona AB, SANION:STO Summary

Markets.ft.com   DA: 14 PA: 32 MOZ Rank: 65

  • Saniona AB is a Sweden-based company active in the field of biotechnology
  • It operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune disea ses
  • The Company develops a technology platform which enables investigation of all types of ion channel drug targets.

Saniona Publishes Its Year-end Report For 2020 Benzinga

Benzinga.com   DA: 16 PA: 50 MOZ Rank: 86

Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients …

SANION, Saniona, (SE0005794617)

Nasdaqomxnordic.com   DA: 23 PA: 17 MOZ Rank: 61

  • 2 Mkt Cap indicates the market value of the selected share series admitted to trading on Nasdaq Nordic
  • Note that the company may have other share series admitted to trading and that it may have unlisted shares
  • For complete information, please visit the company’s website.

Saniona To Present Preclinical Data On SAN903 At The ASPET

Finance.yahoo.com   DA: 17 PA: 50 MOZ Rank: 89

  • Saniona is currently evaluating SAN903 in preclinical models of multiple rare inflammatory and fibrotic disorders and expects to initiate Phase 1 clinical trials in the first half of 2022

Saniona A/S Company Profile Glostrup, Hovedstaden

Dnb.com   DA: 11 PA: 50 MOZ Rank: 84

  • Saniona A/S is located in Glostrup, Hovedstaden, Denmark and is part of the Scientific Research & Development Services Industry
  • Saniona A/S has 35 employees at this location and generates $279,796 in sales (USD)
  • There are 2 companies in the Saniona A/S corporate family.

Saniona Company Profile

Craft.co   DA: 8 PA: 8 MOZ Rank: 40

  • Who are Saniona key executives?
  • Saniona's key executives are Rami Levin, Jørgen Drejer and Anita Milland.
  • How many employees does Saniona have?
  • Competitors of Saniona include Nordic Nanovector, ViewPoint …

Saniona : Announces Oral Presentation Of Tesomet Data In

Marketscreener.com   DA: 22 PA: 50 MOZ Rank: 97

  • Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world
  • The company's lead product candidate, Tesomet, is in mid-stage clinical trials for the rare diseases Prader-Willi syndrome and hypothalamic obesity.

Saniona Receives U.S. FDA Orphan Drug Designation For

Apnews.com   DA: 10 PA: 50 MOZ Rank: 86

  • About Saniona Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world
  • The company’s lead product candidate, Tesomet, is in mid-stage clinical trials for the rare diseases Prader-Willi syndrome and hypothalamic obesity.

Coulter Partners Recruits Chief Medical Officer For Saniona

Huntscanlon.com   DA: 15 PA: 50 MOZ Rank: 92

  • Saniona is a rare disease biopharmaceutical company focused on research, development and commercialization of treatments for the central nervous system
  • The company has four programs in clinical development
  • Saniona intends to develop and commercialize treatments for rare disease indications such as Prader-Willi syndrome and hypothalamic

Saniona AB: Saniona Receives Feedback From U.S. FDA

Finanznachrichten.de   DA: 24 PA: 50 MOZ Rank: 22

  • About Saniona Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world

Saniona AB: Saniona Completes Sale Of Remaining Shares In

Finanznachrichten.de   DA: 24 PA: 50 MOZ Rank: 21

  • About Saniona Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world

Saniona Co-Founds New Migraine-Focused Company BioSpace

Biospace.com   DA: 16 PA: 50 MOZ Rank: 96

  • Denmark-based Saniona, a company focused on treating eating disorders and diseases of the central nervous system, has co-founded a new company that is taking aim at the migraine market.
  • The new company, Cephagenix, will develop novel migraine treatments based on Saniona's unique ion channel competence and CNS technology platform.

BRIEF-Saniona Co-Founds New Migraine Therapy Company

Reuters.com   DA: 15 PA: 50 MOZ Rank: 96

* saniona co-founds new migraine therapy company cephagenix * announces establishment of a new company to identify and develop novel migraine treatments based on saniona’s unique ion channel

Saniona AB: Saniona Receives U.S. FDA Orphan Drug

Finanznachrichten.de   DA: 24 PA: 50 MOZ Rank: 18

  • About Saniona Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world

Saniona Adds Another Target SAN903: What Are The Prospects

Trialsitenews.com   DA: 17 PA: 50 MOZ Rank: 100

  • Saniona assesses that SAN903 is the first ion channel modulator developed for IBD and will thus become first-in-class, reports the company in its press release
  • They have declared that it also has the potential to treat a rare congenital blood disease called hereditary xerocytosis (HX), which is caused by mutations to the IK channel.

Recently Analyzed Sites

Runen.net (2 seconds ago)

Inaturist.com (25 seconds ago)

Alfalaboratory.com (7 seconds ago)

H5constructionllc.com (1 seconds ago)

Madrasafree.net (4 seconds ago)

Thewayprepared.com (26 seconds ago)

Tecneco.com (3 seconds ago)

Cityofdrippingsprings.com (14 seconds ago)

Getbackyourgo.com (15 seconds ago)

Caasint.com (23 seconds ago)

Verticalsims.com (5 seconds ago)

Projectkindle.org (0 seconds ago)

Supermicro.com (9 seconds ago)

Halfcuts.com (18 seconds ago)

Newzealandvisaeta.com (4 seconds ago)

Carbonfiberevent.com (1 seconds ago)

Saniona.com (0 seconds ago)